Try our mobile app

Switch to company model in classical logic    *

General information

Country: BERMUDA

Sector: Biotechnology

Kiniksa Pharmaceuticals, Ltd. doing business as Kiniksa Pharmaceuticals Corp. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals serves patients worldwide.
Website: kiniksa.com



Growth: Good revenue growth rate 61.6%, there is slowdown compared to average historical growth rates 69.3%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +87.0%. On average the margin is improving unsteadily. Gross margin is high, +53.8%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.58 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 4.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 313.8% higher than minimum and 0.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 9.0x by EV / Sales multiple , the company can be 95.8% undervalued

Insiders: For the last 3 months insiders sold company shares on $5.7 mln (-0.189% of cap.)

Key Financials (Download financials)

Ticker: KNSA
Share price, USD:  (0.0%)43.2
year average price 31.99  


year start price 19.49 2025-02-08

min close price 18.65 2025-04-10

max close price 43.52 2025-12-22

current price 43.20 2026-02-07
Common stocks: 71 726 685

Dividend Yield:  0.0%
FCF Yield LTM: 4.2%
EV / LTM EBITDA: 5.3x
EV / EBITDA annualized: 7.0x
EV / Sales: 4.6x
Margin (EBITDA LTM / Revenue): 87.0%
Fundamental value created in LTM:
Market Cap ($m): 3 099
Net Debt ($m): -342
EV (Enterprise Value): 2 757
Price to Book: 5.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-24seekingalpha.com

Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator

2026-01-12seekingalpha.com

Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-10-28zacks.com

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates

2025-09-19zacks.com

Kiniksa Pharmaceuticals International, plc (KNSA) is on the Move, Here's Why the Trend Could be Sustainable

2025-09-03zacks.com

Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why

2025-08-18zacks.com

Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why

2025-07-29zacks.com

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates

2025-05-05seekingalpha.com

Kiniksa Pharmaceuticals: Making Steady Progress

2025-04-29seekingalpha.com

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript

2025-04-29zacks.com

Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-28 2025-07-29 2024-10-29 2024-07-25 2024-04-25 2023-11-02 2023-08-01 2023-05-04 2022-11-03
acceptedDate 2025-10-28 16:15:57 2025-07-29 16:16:01 2025-02-25 16:15:46 2024-10-29 16:14:07 2024-07-25 16:10:34 2024-04-25 16:16:04 2024-02-28 16:16:09 2023-11-02 16:15:43 2023-08-01 16:15:29 2023-05-04 16:15:43 2023-03-02 16:16:15 2022-11-03 16:16:28 2022-02-24 16:16:09 2021-02-25 16:13:42
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 181M 157M 423M 112M 109M 80M 270M 67M 71M 48M 220M 99M 39M 0
costOfRevenue 84M 71M 61M 49M 42M 32M 57M 26M 22M 7M 23M 12M 9M 4M
grossProfit 97M 86M 362M 63M 66M 48M 214M 41M 50M 41M 197M 88M 29M -4M
grossProfitRatio 0.538 0.547 0.56 0.609 0.605 0.606 0.697 0.854 0.883
researchAndDevelopmentExpenses 24M 19M 112M 26M 24M 26M 76M 17M 24M 15M 65M 16M 99M 110M
generalAndAdministrativeExpenses 0 0 157M 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 11M 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 49M 47M 168M 46M 42M 39M 129M 34M 29M 29M 98M 25M 86M 44M
otherExpenses 0 0 128M 0 2M 2M 33M 2M 2M 8M 24M 0 835 000 0
operatingExpenses 73M 66M 408M 72M 66M 65M 239M 52M 53M 53M 188M 41M 186M 154M
costAndExpenses 157M 137M 469M 122M 109M 96M 295M 78M 75M 60M 210M 53M 195M 157M
interestIncome 0 3M 9M 0 0 0 9M 2M 2M 0 1M 322 000 97 000 1M
interestExpense 0 0 0 0 0 0 0 0 0 -2M 0 322 000 0 0
depreciationAndAmortization 384 000 358 000 2M 399 000 430 000 466 000 2M 603 000 602 000 596 000 2M 0 2M 4M
ebitda 28M 21M -44M -10M 313 000 -16M -23M -11M -3M -11M 12M 46M -154M -152M
ebitdaratio 0.152 0.131 -0.086 0.003 -0.201 -0.163 -0.044 -0.232 0.468
operatingIncome 24M 20M -46M -10M -117 000 -17M -25M -11M -3M -11M 10M 46M -157M -157M
operatingIncomeRatio 0.133 0.129 -0.086 -0.001 -0.207 -0.163 -0.044 -0.232 0.468
totalOtherIncomeExpensesNet 3M 3M 9M 2M 2M 2M 9M 2M 2M 2M 1M 322 000 97 000 1M
incomeBeforeTax 27M 23M -36M -7M 2M -14M -17M -8M -1M -9M 11M 47M -157M -156M
incomeBeforeTaxRatio 0.15 0.146 -0.064 0.021 -0.179 -0.127 -0.017 -0.194 0.471
incomeTaxExpense 9M 5M 7M 5M 6M 3M -31M 5M -16M 3M -172M -177M 1M 5M
netIncome 18M 18M -43M -13M -4M -18M 14M -14M 15M -12M 183M 224M -158M -161M
netIncomeRatio 0.102 0.114 -0.113 -0.036 -0.222 -0.207 0.209 -0.254 2.26
eps 0.25 0.24 -0.6 -0.18 -0.055 -0.25 0.2 -0.2 0.21 -0.18 2.64 3.23 -2.3 -2.61
epsdiluted 0.23 0.23 -0.18 -0.055 -0.25 -0.2 0.21 -0.18 3.18
weightedAverageShsOut 74M 73M 71M 72M 71M 71M 70M 70M 72M 70M 69M 69M 69M 62M
weightedAverageShsOutDil 78M 78M 71M 72M 71M 71M 72M 70M 72M 70M 70M 71M 69M 62M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-25 2024-02-28 2023-03-02 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 9M 9M 1M 97 000 1M
ebit -46M -25M 10M -157M -156M
nonOperatingIncomeExcludingInterest 0 0 0 0 -1M
netIncomeFromContinuingOperations -43M 14M 183M -158M -161M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -43M 14M 183M -158M -161M
epsDiluted -0.6 0.2 2.6 -2.3 -2.61

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-28 2025-07-29 2024-10-29 2024-07-25 2024-04-25 2023-11-02 2023-08-01 2023-05-04 2022-11-03
acceptedDate 2025-10-28 16:15:57 2025-07-29 16:16:01 2025-02-25 16:15:46 2024-10-29 16:14:07 2024-07-25 16:10:34 2024-04-25 16:16:04 2024-02-28 16:16:09 2023-11-02 16:15:43 2023-08-01 16:15:29 2023-05-04 16:15:43 2023-03-02 16:16:15 2022-11-03 16:16:28 2022-02-24 16:16:09 2021-02-25 16:13:42
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 175M 192M 184M 97M 99M 141M 108M 118M 113M 81M 123M 176M 122M 114M
shortTermInvestments 177M 116M 60M 126M 119M 72M 98M 83M 72M 107M 68M 25M 60M 209M
cashAndShortTermInvestments 352M 308M 244M 224M 219M 214M 206M 201M 185M 187M 191M 201M 182M 323M
netReceivables 52M 32M 42M 25M 20M 16M 21M 3M 25M 7M 20M 11M 4M 0
inventory 41M 48M 26M 29M 35M 27M 31M 26M 24M 23M 22M 15M 4M 0
otherCurrentAssets 30M 32M 20M 34M 27M 14M 18M 26M 12M 151M 11M 15M 0 210 000
totalCurrentAssets 476M 420M 332M 311M 301M 271M 276M 256M 185M 232M 243M 242M 196M 333M
propertyPlantEquipmentNet 12M 11M 11M 12M 12M 13M 13M 14M 14M 1M 7M 8M 8M 11M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 16M 16M 16M 17M 17M 17M 17M 18M 18M 18M 18M 19M 19M 0
goodwillAndIntangibleAssets 16M 16M 16M 17M 17M 17M 17M 18M 18M 18M 18M 19M 19M 0
longTermInvestments 0 0 0 0 -1 -245M 0 0 0 0 0 0 0 0
taxAssets 201M 206M 211M 208M 204M 215M 219M 194M 204M 184M 185M 186M 0 10000
otherNonCurrentAssets 8M 8M 10M 8M 8M 249M 827 000 2M 2M 8M 6M 6M 9M 6M
totalNonCurrentAssets 237M 241M 249M 244M 241M 249M 250M 227M 238M 211M 217M 218M 36M 16M
otherAssets 0 0 0 0 1 0 0 0 61M 0 0 0 0 0
totalAssets 712M 661M 581M 555M 542M 520M 526M 483M 484M 443M 460M 460M 233M 349M
accountPayables 6M 9M 2M 8M 7M 6M 8M 1M 648 000 1M 8M 1M 2M 503 000
shortTermDebt 3M 3M 0 4M 4M 2M 0 2M 2M 3M 0 3M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 32M 0 0 12 000 156 000 307 000 3M 5M 6M 0 12M 0 0
otherCurrentLiabilities 115M 75M 97M 84M 73M 56M 37M 48M 40M 25M 17M 40M 2M 8M
totalCurrentLiabilities 124M 118M 101M 96M 84M 64M 64M 53M 47M 37M 47M 56M 45M 32M
longTermDebt 7M 7M 0 9M 9M 10M 0 11M 11M 2M 0 3M 0 0
deferredRevenueNonCurrent 32M 32M 32M 12M 12M 12M 12M 12M 12M 12M 12M 14M 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 15M 9M 2M 2M 2M 2M 2M 2M 2M 2M 2M 3M 270 000 805 000
totalNonCurrentLiabilities 53M 48M 41M 22M 23M 24M 24M 24M 25M 16M 16M 19M 3M 6M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 10M 10M 10M 11M 11M 10M 12M 13M 14M 6M 6M 7M 6M 7M
totalLiabilities 177M 166M 142M 118M 107M 88M 87M 78M 73M 53M 64M 76M 48M 38M
preferredStock 0 0 0 0 110 000 0 0 0 0 0 0 0 0 0
commonStock 21 000 21 000 20 000 20 000 20 000 20 000 20 000 15 000 14 000 14 000 19 000 19 000 18 000 18 000
retainedEarnings -476M -495M -521M -512M -500M -496M -478M -503M -489M -504M -492M -496M -675M -517M
accumulatedOtherComprehensiveIncomeLoss -155 000 -53 000 -163 000 -41 000 -130 000 -53 000 6000 -1000 13 000 55 000 44 000 -70 000 -66 000 -34 000
othertotalStockholdersEquity 1 012M 990M 949M 935M 928M -14 000 -27 000 -69 000 51 000
totalStockholdersEquity 535M 495M 438M 437M 435M 432M 439M -503M -489M -504M 396M -496M 185M 312M
totalEquity 535M 495M 438M 437M 435M 432M 439M -503M -489M -504M 396M -496M 185M 312M
totalLiabilitiesAndStockholdersEquity 712M 661M 555M 542M 520M -425M -417M -452M -421M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 712M 661M 581M 555M 542M 520M 526M -425M -417M -452M 460M -421M 233M 349M
totalInvestments 177M 116M 60M 126M 119M 72M 98M 83M 72M 107M 68M 25M 60M 209M
totalDebt 10M 10M 10M 11M 11M 12M 12M 13M 14M 6M 6M 7M 6M 7M
netDebt -165M -182M -174M -87M -88M -129M -96M -105M -99M -75M -117M -169M -116M -107M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-25 2024-02-28 2023-03-02 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 42M 21M 13M 4M 0
otherReceivables 0 0 8M 0 0
prepaids 0 0 0 7M 10M
totalPayables 2M 8M 8M 2M 503 000
otherPayables 0 0 0 0 0
accruedExpenses 0 16M 19M 38M 21M
capitalLeaseObligationsCurrent 2M 2M 3M 3M 2M
capitalLeaseObligationsNonCurrent 8M 10M 3M 3M 5M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 960M 917M 888M 860M 829M
otherTotalStockholdersEquity 0 0 0 -0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA KNSA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-28 2025-07-29 2024-10-29 2024-07-25 2024-04-25 2023-11-02 2023-08-01 2023-05-04 2022-11-03
acceptedDate 2025-10-28 16:15:57 2025-07-29 16:16:01 2025-02-25 16:15:46 2024-10-29 16:14:07 2024-07-25 16:10:34 2024-04-25 16:16:04 2024-02-28 16:16:09 2023-11-02 16:15:43 2023-08-01 16:15:29 2023-05-04 16:15:43 2023-03-02 16:16:15 2022-11-03 16:16:28 2022-02-24 16:16:09 2021-02-25 16:13:42
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 18M 18M -43M -13M -4M -18M 14M -14M 15M -12M 183M 224M -158M -161M
depreciationAndAmortization 384 000 358 000 2M 399 000 430 000 466 000 2M 603 000 602 000 596 000 2M 493 000 2M 2M
deferredIncomeTax 4M 3M 8M -4M 11M 4M -34M 10M -19M 1M -185M 0 11 000 4M
stockBasedCompensation 10M 9M 31M 8M 7M 7M 27M 7M 6M 6M 25M 6M 25M 21M
changeInWorkingCapital -1M -2M 25M 6M -10M 9M 1M 11M -6M 260 000 -23M 17M 689 000 -4M
accountsReceivables -20M 8M -20M -4M -4M 5M -950 000 22M -17M 5M -16M -3M -4M 0
inventory 7M -26M 5M 6M -8M 4M -10M -2M -533 000 -2M -18M 5M -4M 0
accountsPayables -3M 7M -6M 911 000 2M -3M 347 000 364 000 -743 000 -7M 6M -1M 1M -5M
otherWorkingCapital 15M 9M 47M 3M 397 000 2M 11M -9M 13M 3M 6M 16M 7M 654 000
otherNonCashItems 2M 46 000 4M 267 000 19M 3M 2M 2M -383 000 -45 000 3M -185M 3M 2M
netCashProvidedByOperatingActivities 34M 28M 26M -2M 5M 4M 13M 17M -4M -4M 6M 62M -126M -137M
investmentsInPropertyPlantAndEquipment -671 000 -165 000 -277 000 0 0 -84 000 -130 000 -16 000 -34 000 -24 000 -105 000 -22 000 -415 000 -283 000
acquisitionsNet 0 0 25 000 -25 000 25 000 0 0 12M -36M 0 0 0 0 23M
purchasesOfInvestments -146M -34M -202M -54M -89M -36M -205M -53M -38M -53M -136M -17M -157M -430M
salesMaturitiesOfInvestments 84M 31M 240M 48M 42M 62M 176M 41M 74M 15M 128M 36M 306M 407M
otherInvestingActivites 0 0 25 000 -47M 26M -12M 36M 0 -10000
netCashUsedForInvestingActivites -63M -4M -6M -47M 26M -12M 36M -38M 19M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 0 0 4M 552 000 158 000 0 0
commonStockRepurchased -4M -2M -5M -3M -1M -381 000 -2M -1M -419 000 -420 000 0 -208 000 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 16M 13M 9M 1M -381 000 1M 419 000 510 000 569 000
netCashUsedProvidedByFinancingActivities 12M 11M 7M -178 000 4M 552 000 158 000 90 000 361 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash -17M 35M 76M -2M -42M 33M -15M 5M 32M -42M 245 000 81M 8M 67M
cashAtEndOfPeriod 175M 192M 184M 97M 99M 141M 108M 118M 113M 81M 123M 176M 122M 114M
cashAtBeginningOfPeriod 192M 157M 108M 99M 141M 108M 123M 113M 81M 123M 122M 94M 114M 47M
operatingCashFlow 34M 28M 26M -2M 5M 4M 13M 17M -4M -4M 6M 62M -126M -137M
capitalExpenditure -671 000 -165 000 -277 000 0 0 -84 000 -130 000 -16 000 -34 000 -24 000 -105 000 -22 000 -20M -283 000
freeCashFlow 33M 28M 25M -2M 5M 4M 13M 17M -4M -4M 6M 62M -147M -137M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-25 2024-02-28 2023-03-02 2022-02-24 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 91 000 -20M -23M
netCashProvidedByInvestingActivities 38M -30M -8M 129M -23M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -5M -2M 3M 0 228M
netCommonStockIssuance -5M -2M 3M 0 228M
commonStockIssuance 0 0 3M 0 228M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 17M 4M -901 000 6M -1M
netCashProvidedByFinancingActivities 12M 1M 3M 6M 227M
incomeTaxesPaid 2M 6M 11M 1M 482 000
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-10-28 ET (fiscal 2025 q3)
2025 q2
2025-07-29 ET (fiscal 2025 q2)
2025 q1
2025-04-29 ET (fiscal 2025 q1)
2024 q4
2025-02-25 ET (fiscal 2024 q4)
2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-07-23 ET (fiscal 2024 q2)
2024 q1
2024-04-23 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-07-25 ET (fiscal 2023 q2)
2023 q1
2023-05-06 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-05 ET (fiscal 2022 q2)
2022 q1
2022-05-07 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-10-28 20:15 ET
Kiniksa Pharmaceuticals reported for 2025 q3
SEC form 8
2025-10-28 11:39 ET
Kiniksa Pharmaceuticals published news for 2025 q3
SEC form 8
2025-10-28 11:39 ET
Kiniksa Pharmaceuticals published news for 2025 q3
SEC form 10
2025-07-29 20:16 ET
Kiniksa Pharmaceuticals reported for 2025 q2
SEC form 8
2025-07-29 11:30 ET
Kiniksa Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-29 11:30 ET
Kiniksa Pharmaceuticals published news for 2025 q2
SEC form 10
2025-04-29 20:15 ET
Kiniksa Pharmaceuticals reported for 2025 q1
SEC form 8
2025-04-29 11:40 ET
Kiniksa Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-29 11:40 ET
Kiniksa Pharmaceuticals published news for 2025 q1
SEC form 10
2025-04-29 00:00 ET
Kiniksa Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-25 00:00 ET
Kiniksa Pharmaceuticals reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Kiniksa Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Kiniksa Pharmaceuticals published news for 2024 q4
SEC form 10
2024-10-29 16:14 ET
Kiniksa Pharmaceuticals reported for 2024 q3
SEC form 8
2024-10-29 07:31 ET
Kiniksa Pharmaceuticals published news for 2024 q3
SEC form 8
2024-10-29 07:31 ET
Kiniksa Pharmaceuticals published news for 2024 q3
SEC form 10
2024-10-29 00:00 ET
Kiniksa Pharmaceuticals published news for 2024 q3
SEC form 10
2024-07-25 00:00 ET
Kiniksa Pharmaceuticals published news for 2024 q2
SEC form 8
2024-07-23 00:00 ET
Kiniksa Pharmaceuticals published news for 2024 q2
SEC form 8
2024-07-23 00:00 ET
Kiniksa Pharmaceuticals reported for 2024 q2
SEC form 10
2024-04-25 00:00 ET
Kiniksa Pharmaceuticals published news for 2024 q1
SEC form 8
2024-04-23 07:34 ET
Kiniksa Pharmaceuticals reported for 2024 q1
SEC form 8
2024-04-23 07:34 ET
Kiniksa Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-28 16:16 ET
Kiniksa Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-28 07:35 ET
Kiniksa Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-28 07:35 ET
Kiniksa Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-02 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q3
SEC form 8
2023-10-31 07:35 ET
Kiniksa Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-01 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-25 07:40 ET
Kiniksa Pharmaceuticals reported for 2023 q2
SEC form 8
2023-07-25 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-07 17:09 ET
Kiniksa Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-02 00:00 ET
Kiniksa Pharmaceuticals published news for 2023 q1
SEC form 6
2023-04-27 16:43 ET
Kiniksa Pharmaceuticals published news for 2023 q1
SEC form 6
2023-03-10 20:51 ET
Kiniksa Pharmaceuticals published news for 2022 q4
SEC form 10
2023-03-02 16:16 ET
Kiniksa Pharmaceuticals reported for 2022 q4
SEC form 10
2023-03-02 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-28 08:17 ET
Kiniksa Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-09 08:05 ET
Kiniksa Pharmaceuticals published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Kiniksa Pharmaceuticals published news for 2022 q4
SEC form 10
2022-11-03 16:16 ET
Kiniksa Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-01 08:06 ET
Kiniksa Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q3
SEC form 10
2022-08-04 16:17 ET
Kiniksa Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-03 07:35 ET
Kiniksa Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-30 16:13 ET
Kiniksa Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-05 16:16 ET
Kiniksa Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-03 09:09 ET
Kiniksa Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Kiniksa Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-28 16:43 ET
Kiniksa Pharmaceuticals published news for 2022 q1
SEC form 10
2022-02-24 16:16 ET
Kiniksa Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-22 08:06 ET
Kiniksa Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-10 08:56 ET
Kiniksa Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-03 16:39 ET
Kiniksa Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-04 16:51 ET
Kiniksa Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-01 08:06 ET
Kiniksa Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-01 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-05 16:31 ET
Kiniksa Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-03 08:09 ET
Kiniksa Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-06 17:08 ET
Kiniksa Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-21 17:37 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-21 17:37 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-12 17:02 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 16:30 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-04 08:07 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-28 16:34 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-28 16:05 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-15 17:32 ET
Kiniksa Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-03 16:29 ET
Kiniksa Pharmaceuticals published news for 2020 q4
SEC form 10
2021-02-25 16:13 ET
Kiniksa Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 08:04 ET
Kiniksa Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-11 08:08 ET
Kiniksa Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-23 17:03 ET
Kiniksa Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-22 16:02 ET
Kiniksa Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-10 16:22 ET
Kiniksa Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-05 16:28 ET
Kiniksa Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-05 07:33 ET
Kiniksa Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-26 08:04 ET
Kiniksa Pharmaceuticals published news for 2020 q3